#United States #San Diego #Multiple Sclerosis #Immunic #Vidofludimus Calcium

Immunic Presents Plan for Vidofludimus Calcium at ACTRIMS Forum 2026

Immunic, Inc., a leading biotechnology firm, is all set to unveil new data from its Phase 2 CALLIPER trial for their promising oral therapy, Vidofludimus Calcium, during the ACTRIMS Forum 2026 scheduled for February 5-7 in San Diego, California. This presentation aims to further affirm the drug's potential benefits for individuals struggling with progressive multiple sclerosis (PMS).

The Phase 2 data will highlight the drug’s unique mechanism of action, showcasing how it influences critical biological pathways associated with PMS progression. As per Daniel Vitt, Ph.D., the CEO of Immunic, the compelling findings from the CALLIPER trial provide evidence of the therapeutic benefits of Vidofludimus Calcium on both inflammatory responses and neurological deterioration linked to the disease.

Presentation Highlights

Two posters presenting the CALLIPER trial findings will be showcased at the forum. The first focuses on the effects of Vidofludimus Calcium on MRI outcomes in patients with PMS. It demonstrates that patients treated with the drug exhibited significant reductions in MRI markers indicative of acute-focal and chronic-compartmentalized inflammation. Specifically, the proportion of patients with gadolinium-enhancing lesions decreased substantially with extended treatment, indicating the drug's ability to mitigate acute disease activity.

Poster Title: Effect of Vidofludimus Calcium, a Novel Nurr1 Activator and Selective DHODH Inhibitor, on MRI Outcomes in Progressive Multiple Sclerosis, presented by Andreas Muehler, M.D.

Additionally, the second poster delves into the antiviral properties of Vidofludimus Calcium, particularly its impact on Epstein-Barr virus (EBV) reactivation, a crucial factor in multiple sclerosis. Notably, the study tracked changes in the T-cell receptor repertoire among participants, revealing a reduction in EBV-specific T-cell responses among those administered the drug compared to a placebo cohort.

Poster Title: Effect of Vidofludimus Calcium on the Anti-EBV T-cell Receptor Repertoire in Progressive Multiple Sclerosis, presented by Amelie Schreieck, Ph.D.

Trial Insights

The insights gained from these analyses reinforce the drug's broad-spectrum antiviral effects and its potential to alter the disease trajectory in patients with MS. The selectivity of Vidofludimus Calcium in targeting pathways responsible for both neuroprotection and inflammation offers a dual mechanism that could revolutionize treatment paradigms for multiple sclerosis.

With successful Phase 2 results underlining the efficacy of Vidofludimus Calcium, Immunic is advancing toward Phase 3 trials, expected to be pivotal for future regulatory approvals. This commitment to tackling PMS and its complexities could offer a ray of hope to countless patients seeking better therapies.

Conclusion

As Immunic gears up for the ACTRIMS Forum 2026, the anticipation builds around the promising trajectory of Vidofludimus Calcium in managing progressive multiple sclerosis. With the backing of robust clinical data, Immunic aims to make strides in providing innovative solutions that address the unmet needs of MS patients worldwide.

For live updates and further information regarding the presentations, attendees can visit Immunic’s website or connect with the management team at the event. As these findings unfold, the potential of Vidofludimus Calcium continues to shine as a beacon of hope for those affected by this challenging condition.